Clinical Trials Logo

Idiopathic Pulmonary Fibrosis clinical trials

View clinical trials related to Idiopathic Pulmonary Fibrosis.

Filter by:

NCT ID: NCT06189820 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

FAPIPET
Start date: March 9, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

NCT ID: NCT06160440 Completed - Pulmonary Fibrosis Clinical Trials

The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.

Start date: June 3, 2021
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011,in health conditions. The main questions it aims to answer are: Safety and tolerability profiles in healthy subjects.Pharmacokinetic profiles in healthy subjects.Food effect in healthy subjects.Participants will complete the study including screening period, dosing period, and observation period. Researchers will compare the inhibitory activity of SC1011 tablets with pirfenidone capsules against the same biomarkers(e.g. blood TNFα) to see if they are different between the two drugs.

NCT ID: NCT06135363 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects

Start date: August 11, 2022
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011 in healthy conditions. The main questions it aims to answer are: Safety and tolerability profiles in healthy subjects and pharmacokinetic profiles in healthy subjects. Participants will complete the study including screening period, dosing period, and observation period. Investigators will compare the inhibitory activity of SC1011 tablets with pirfenidone capsules against the same biomarkers(e.g. blood TNFα) to see if they are different between the two drugs.

NCT ID: NCT06132256 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Start date: December 11, 2023
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

NCT ID: NCT06125327 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Start date: June 6, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of Sufenidone (SC1011) in patients with IPF, and to provide a new safe and effective treatment option for patients with IPF. Participants will complete the study including screening period, treating period, and follow-up period. Investigators will compare the annual rate of decline in FVC to see if it is an optional new drug. The participants have lung function tests at study visits. The results of the lung function tests are compared between the SC1011 groups and the placebo group. The doctors also regularly check the general health of the participants.

NCT ID: NCT06102083 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

Start date: November 2, 2023
Phase: Phase 2
Study type: Interventional

This trial was performed in patients with idiopathic pulmonary fibrosis (IPF) to evaluate the clinical efficacy and safety of different doses of TDI01 Suspension, compared with control, for the treatment of patients with IPF.

NCT ID: NCT06097260 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Start date: November 16, 2023
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

NCT ID: NCT06081621 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

Start date: October 20, 2023
Phase: Phase 2
Study type: Interventional

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.

NCT ID: NCT06049004 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Londrina Activities of Daily Living Protocol in Idiopathic Pulmonary Fibrosis Patients

Start date: November 1, 2023
Phase:
Study type: Observational [Patient Registry]

The Londrina Activities of Daily Living Protocol was first developed for Chronic Obstructive Pulmonary Disease patients and was found to be valid and reliable, but there is no validity and reliability study of the Londrina Activities of Daily Living Protocol in IPF patients. The purpose of the study is to Examine the Validity and Reliability of the Londrina Activities of Daily Living Protocol in Idiopathic Pulmonary Fibrosis (IPF) patients.

NCT ID: NCT06037408 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

The Effect of N115 on Coughing in IPF Patients

Start date: August 15, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to administer a sodium pyruvate nasal spray that eliminates nasal oxidative stresses, caused by oxygen radicals, and demonstrate the efficacy of sodium pyruvate to reduce coughing and increase lung functions in patients with idiopathic pulmonary fibrosis. This will be a 21-day double-blinded randomized placebo-controlled trial designed to determine if patients with idiopathic pulmonary fibrosis treated with 20mM sodium pyruvate in 0.9% sodium chloride nasal spray solution will have reduced chronic coughing, as well as increased lung function (FEV1, FVC endpoints of 12% or more within the first week) and improved FEV1/FVC ratios.